Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

BioAge Labs Completes IND-Enabling Studies For BGE-102 And Advances Candidate Toward Clinic

Author: Benzinga Newsdesk | May 29, 2025 08:04am

IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end

BGE-102 induced weight loss in preclinical obesity models, both as monotherapy and in combination with GLP-1 receptor agonists



Internally discovered compound has a novel binding site and potential best-in-class profile supporting once daily dosing

Posted In: BIOA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist